Matthew L. Sherman Unloads 5,000 Shares of Acceleron Pharma Stock (XLRN)
Acceleron Pharma (NASDAQ:XLRN) SVP Matthew L. Sherman unloaded 5,000 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $25.82, for a total transaction of $129,100.00. Following the sale, the senior vice president now directly owns 27,858 shares in the company, valued at approximately $719,294. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
XLRN has been the subject of a number of recent research reports. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday, August 14th. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday, August 13th. They set an “outperform” rating and a $47.00 price target on the stock. Four analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $51.00.
Acceleron Pharma (NASDAQ:XLRN) traded up 1.17% on Thursday, hitting $26.00. The stock had a trading volume of 139,049 shares. Acceleron Pharma has a 52-week low of $16.78 and a 52-week high of $57.89. The stock has a 50-day moving average of $28.3 and a 200-day moving average of $34.30. The company’s market cap is $826.7 million.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.01. On average, analysts predict that Acceleron Pharma will post $-1.44 earnings per share for the current fiscal year.
Acceleron Pharma Inc is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.